<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Female urinary incontinence: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Female urinary incontinence: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Female urinary incontinence: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily S Lukacz, MD, MAS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Linda Brubaker, MD, FACOG</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16614005"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Female urinary incontinence is a common yet undertreated problem globally. Treatment typically begins with lifestyle modification, pelvic floor muscle training, and topical vaginal estrogen as indicated. Those who do not respond adequately, or desire surgical intervention, can proceed with procedures targeted at the specific mechanism of urinary incontinence. This topic will discuss the treatment of urinary incontinence in nonpregnant adult females with a focus on the initial management of stress and stress predominant mixed urinary incontinence (MUI), overflow, and functional incontinence.</p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of urgency urinary incontinence/overactive bladder (OAB) and urge predominant MUI is described separately. (See  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation of urinary incontinence, for both males and females, and incontinence related to pregnancy and delivery are discussed separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/14611.html" rel="external">"Urinary incontinence in men"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/8079.html" rel="external">"Effect of pregnancy and childbirth on urinary incontinence and pelvic organ prolapse"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H3251828434"><span class="h1">EVIDENCE OF UNDERTREATMENT</span><span class="headingEndMark"> — </span>Urinary incontinence, the involuntary leakage of urine, is often underdiagnosed and undertreated [<a href="#rid1">1-3</a>]. In one survey, nearly three out of four women with urinary incontinence hadn't addressed the issue with their general practitioner, with the most common reasons being that they were "too embarrassed, too busy, or worried about wasting the doctor's time" [<a href="#rid4">4</a>]. In another study, only 60 percent of patients seeking care for leakage (at least once weekly) recalled receiving any treatment for their incontinence [<a href="#rid5">5</a>]. Additionally, nearly 50 percent of those who did receive treatment reported moderate to great frustration with ongoing incontinence.</p><p class="headingAnchor" id="H16614073"><span class="h1">PRIOR TO INITIATING TREATMENT</span></p><p class="headingAnchor" id="H16614079"><span class="h2">Identify indications for referral</span><span class="headingEndMark"> — </span>Indications for further evaluation or referral for treatment of urinary incontinence include the sudden onset of incontinence (particularly with additional neurologic symptoms), presence of associated abdominal/pelvic pain, gross or microscopic hematuria in the absence of urinary tract infection, culture-documented recurrent urinary tract infections, new neurologic symptoms, suspected urinary fistula or urethral diverticulum, chronic catheterization, difficulty passing a urinary catheter, pelvic organ prolapse beyond the hymen, history of pelvic reconstructive surgery or pelvic irradiation, urinary retention, or persistently elevated postvoid residual (after treatment of possible causes).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Specialist referral'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8075.html" rel="external">"Urethral diverticulum in females"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8071.html" rel="external">"Urogenital tract fistulas in females"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98554.html" rel="external">"Chronic urinary retention in females"</a>.)</p><p></p><p class="headingAnchor" id="H16614114"><span class="h2">Assess incontinence type and severity</span><span class="headingEndMark"> — </span>Determining the classification of urinary incontinence type (stress, urgency, mixed) can help direct treatment.</p><p>Treatment of urinary incontinence should proceed in a stepwise fashion with emphasis on improving quality of life. Risks and side effects of therapy should be carefully balanced with benefits and aligned with patient goals and expectations. While most women with incontinence will have an improvement in symptoms with therapy, some do not achieve full continence. Expectations about the effect of treatment should be discussed with the patient when initiating therapy. (See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voiding diary</strong> – A baseline assessment of symptom severity with a voiding diary  (<a class="graphic graphic_form graphicRef69130" href="/z/d/graphic/69130.html" rel="external">form 1</a>) provides insight into fluid intake and output that can be used to counsel women about appropriate fluid intake, voiding frequency and bladder volumes. A voiding diary can also give an objective assessment of severity and may be helpful in assessing impact of treatment.</p><p></p><p class="bulletIndent1">Examples of voiding diaries can be found online:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>International Urogynecological Association (IUGA) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.yourpelvicfloor.org%2Fmedia%2FBladder_Diary-5.pdf&amp;token=3BBziCZQDrEhIlt93szQlvh%2Bwz7GxJKnLPTJsm%2Bp27bJjCX0Op0sC%2BdeLgIC9n1WLJqKiLPHr2nkq6pW%2Bpg7m4rl0cIldb0ieWFIngE4y9s%3D&amp;TOPIC_ID=6881" target="_blank">IUGA Bladder Diary</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>National Institute of Diabetes and Digestive and Kidney Diseases (US) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Furologic-diseases%2Fbladder-control-problems%2Fdiagnosis&amp;token=Etxqj%2B4B5eylkJgA7xEKfQYRWRXGhdL7dWe%2FkEfUQdZXpr%2BDw7DI%2BQYKAVonIgF%2BysDc2uadVZOzrngGTd2tAr%2FPmSsZ2r%2Fp8xNyqZ2pw4ZCxVrlO4ayKm6ERldAbNl9&amp;TOPIC_ID=6881" target="_blank">Bladder Diary</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>National Association for Continence (US) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnafc.org%2Fwp-content%2Fuploads%2F2022%2F05%2Fbladder-diary.pdf&amp;token=JenESfljl5qbrYB1bD5ksL0mN%2Be6%2B3UWwAaqvP8aOtz9aDDjUWfNjOSzM6sm%2FBH5ygqr3osvjPKqaUdpAxcqJZhaNhJWRSEMM67TLBRlCEA%3D&amp;TOPIC_ID=6881" target="_blank">NAFC Bladder Diary</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quality of life assessment</strong> – Tools are available to assess the impact of incontinence on a patient's quality of life, which can aid in baseline assessment, focus treatment goals, and evaluate treatment efficacy. Tools that patients can complete include the International Consultation on Incontinence Questionnaire, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fcg171%2Fresources%2Fthe-kings-health-questionnaire-191574685&amp;token=vswrgKzfXgkaOfLVc3HIFH3j3ew7V0R0RnUX0nZfvgBwOUAxcqhp0mm40Uxr8udtPOO3%2FOwKuScQE8EBpoNxD%2FN6dsvbyTC3xHzE4yOBqkZXakfgqzmPd9yugF8JmWBC&amp;TOPIC_ID=6881" target="_blank">The King's Health Questionnaire</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sralab.org%2Fsites%2Fdefault%2Ffiles%2F2017-06%2FWUC_Pelvic_Floor_Questionnaire.pdf&amp;token=%2FU9XyVMCWWKexGlstDR2f8cYx7dYefyk561I%2Bs152mD6ETxIT9xuci9WDM3UHMhk5O64QOQVtCT1kBfyyaz0vRc7wD9pFsDxRupQVysHQ1GPP5qVaKoC%2BIbKQwXFu5Re&amp;TOPIC_ID=6881" target="_blank">Pelvic Floor Distress Inventory</a>, Pelvic Floor Impact Questionnaire, and Overactive Bladder Symptoms Score (OABSS) [<a href="#rid6">6</a>]. The Patient Global Impression of Improvement (PGII) and the Patient Global Impression of Severity (PGIS)  (<a class="graphic graphic_table graphicRef101004" href="/z/d/graphic/101004.html" rel="external">table 1</a>) are simple questionnaires that can document treatment progress in a reliable way [<a href="#rid7">7,8</a>].</p><p></p><p class="headingAnchor" id="H16614161"><span class="h2">Symptom management with pads and/or wicking catheters</span><span class="headingEndMark"> — </span>Although pads, protective garments, and moisture-wicking catheters do not address the underlying cause of urinary leakage, many individuals use them for leakage control.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pads and protective garments</strong> – Pads designed for incontinence are preferred over menstrual pads, as menstrual pads have poor absorbency for urine. Disposable underwear designed to absorb large volumes of fluid are also available. While protective items are available at minimal to no cost in many European countries, in the United States these items are costly and rarely covered by insurance, except Medicaid.</p><p></p><p class="bulletIndent1">Chronic exposure to urine-soaked pads can result in contact dermatitis and skin breakdown. Minimizing leakage and ensuring regular changes when leakage occurs are important, especially when used in a nursing home setting. (See  <a class="medical medical_review" href="/z/d/html/2885.html" rel="external">"Prevention of pressure-induced skin and soft tissue injury", section on 'Minimize excess temperature and moisture'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moisture-wicking catheters</strong> – External moisture-wicking catheters remove urine as it is voided with the goal of minimizing perineal moisture and the associated skin breakdown that can result [<a href="#rid9">9,10</a>]. The device involves a disposable suction catheter that is inserted in the patient's underwear or diaper and hooked up to an external suction unit. It is particularly useful for patients with limited mobility and/or ability to independently toilet. Small feasibility studies have reported reductions in use of indwelling catheters and resultant catheter-associated urinary tract infections when external urinary catheters are used instead [<a href="#rid11">11-13</a>].</p><p></p><p>Information on pad varieties and other urinary incontinence supplies is available from medical supply companies and United States-based urinary incontinence patient advocacy groups, such as <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.simonfoundation.org%2F&amp;token=M%2BTIq2EjbF2f7roHJPpS%2FaaQrujUANwzObclvZc49EnQ6NjiuQyeiUitMonFyc7F&amp;TOPIC_ID=6881" target="_blank">The Simon Foundation</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.nafc.org%2F&amp;token=W%2BV6hvKS0rORATNdvWG3UyPSXt5Wk3jfPDHQKHC8kQQ%3D&amp;TOPIC_ID=6881" target="_blank">National Association for Continence</a>. Women should be counseled that leakage is <strong>not</strong> a normal part of aging and that goals of treatment include minimizing or eliminating the need for the use of pads as a self-management strategy.</p><p class="headingAnchor" id="H16614179"><span class="h1">INITIAL TREATMENT</span><span class="headingEndMark"> — </span>Initial treatments for most types of incontinence (stress, urgency, or mixed) include lifestyle modifications and pelvic floor muscle exercise, along with bladder training in women with urgency incontinence and in some women with stress incontinence [<a href="#rid14">14-20</a>]. We typically treat with these conservative therapies for six weeks before considering subsequent therapies. Assuming evidence of some progress, it is also reasonable to treat with conservative therapies for up to six months, particularly in obese women who are likely to experience improved bladder control following weight loss.</p><p class="headingAnchor" id="H16614264"><span class="h2">Modifying contributory factors</span><span class="headingEndMark"> — </span>Before starting any treatment for urinary incontinence, contributory factors such as medical conditions and medications should be addressed, particularly in older patients  (<a class="graphic graphic_table graphicRef101070" href="/z/d/graphic/101070.html" rel="external">table 2</a>) [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Other contributing factors/conditions'</a>.)</p><p class="headingAnchor" id="H16614296"><span class="h2">Lifestyle modification</span><span class="headingEndMark"> — </span>Weight loss in obese women has many benefits, including improvement of urinary incontinence symptoms. Although commonly recommended and generally low risk, other lifestyle modifications that focus on dietary changes, fluid restriction, and caffeine reduction have been less studied [<a href="#rid22">22</a>]. At least one study has reported that support group teaching of these approaches improved urinary and bowel incontinence symptoms in women [<a href="#rid23">23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight loss</strong> – Obesity is a known risk factor for urinary incontinence, and weight loss in obese women appears to improve symptoms of urinary incontinence [<a href="#rid22">22,24-30</a>]. Studies show greater benefits for stress incontinence than urgency incontinence. For example, one randomized trial of 338 overweight and obese women (mean body mass index [BMI] 36 kg/m<sup>2</sup>) found that weekly incontinence episodes decreased in women assigned to an intensive six-month weight loss program compared with a control group (47 versus 28 percent) [<a href="#rid24">24</a>]. Mean weight loss was 7.8 kg in the intervention group and 1.5 kg in the control group. While the difference in the groups was driven by a decrease in episodes of stress incontinence but not urgency incontinence, more women in the intervention group had a ≥70 percent reduction in the frequency of all incontinence episodes. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary changes</strong> – Some beverages may exacerbate symptoms of urinary incontinence [<a href="#rid31">31</a>]. We ask patients to reduce consumption of alcoholic, caffeinated, and carbonated beverages [<a href="#rid32">32,33</a>]. Women who are drinking excess amounts of liquids (&gt;64 ounces of liquids) should normalize their fluid intake, unless there is a medical reason why they need to consume more liquids. We do not restrict fluid consumption below this level as this can lead to dehydration. Women are advised to consume liquids (mostly water) in small amounts of throughout the day, rather than drinking large volumes at one time. We also ask women who complain of nocturia to decrease or eliminate liquid consumed after dinner (or within several hours before bedtime). (See  <a class="medical medical_review" href="/z/d/html/6877.html" rel="external">"Nocturia: Clinical presentation, evaluation, and management in adults", section on 'Initial measures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constipation</strong> – Constipation can exacerbate urinary incontinence and increase the risks of urinary retention [<a href="#rid34">34</a>]. Constipation should be treated as indicated. (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking cessation</strong> – Smoking has been associated with an increased risk for urinary incontinence [<a href="#rid33">33,35</a>]. Beyond the general health benefits of smoking cessation, no studies have evaluated whether smoking cessation decreases urinary incontinence. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="headingAnchor" id="H16614557"><span class="h2">Pelvic floor muscle (Kegel) exercises</span><span class="headingEndMark"> — </span>Consistent with guidelines from the American College of Physicians, we suggest pelvic floor muscle (Kegel) exercises for women with urinary incontinence, particularly stress urinary incontinence [<a href="#rid36">36</a>]. Pelvic muscle (Kegel) exercises strengthen the pelvic floor musculature to provide a backboard for the urethra to compress on and to reflexively inhibit detrusor contractions. Information on anatomy, exercises, and patient counseling are available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F378%2Fbmj-2022-070186&amp;token=cQPYGFzowbrgeI4ozEoovnnkAcMfzyOZR3N24vVpT%2FzG%2FeYZGgKa03jQE9lMsedgLyVnLobWJHUPBXewxXbzpw%3D%3D&amp;TOPIC_ID=6881" target="_blank">online</a> [<a href="#rid37">37</a>]. </p><p class="headingAnchor" id="H16614563"><span class="h3">Initial instructions</span><span class="headingEndMark"> — </span>These exercises can be effective for both stress and urgency incontinence [<a href="#rid38">38</a>] (see  <a class="medical medical_patient" href="/z/d/html/8403.html" rel="external">"Patient education: Pelvic floor muscle exercises (Beyond the Basics)"</a>). The basic regimen consists of three sets of 8 to 12 contractions sustained for 8 to 10 seconds each, performed three times a day [<a href="#rid37">37</a>]. Patients should try to do this every day and continue for at least 15 to 20 weeks [<a href="#rid39">39</a>].</p><p>A systematic review of randomized trials found that, compared with no treatment, women treated with pelvic muscle exercises were more likely to report improvement or cure of any urinary incontinence (67 versus 29 percent; relative risk [RR] 2.39; 95% CI 1.64-3.47) [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Stress urinary incontinence'</a> and  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Urgency urinary incontinence'</a>.)</p><p>Patients have better outcomes with regular exercise and proper technique. Adequacy of pelvic floor muscle contraction can be assessed during the pelvic examination. The examiner places one or two fingers within the vagina and asks the patient to contract her pelvic floor using the same muscles she would use to stop urine flow or bowel gas [<a href="#rid40">40</a>]. In women who are able to isolate their pelvic floor muscles to stop urine flow, verbal instruction on timing and frequency of exercise is usually sufficient. For those with difficulty identifying the proper muscles, supplemental modalities can help women to perform these exercises properly.</p><p class="headingAnchor" id="H1487896463"><span class="h3">Supplemental modalities</span><span class="headingEndMark"> — </span>For women who are able to isolate pelvic floor musculature, supplemental therapy may not be necessary. However, other patients may have difficulty because of poor muscle isolation, low motivation, or inability to properly contract the pelvic floor. For these patients, we use supplemental therapies such as supervised pelvic floor therapy, vaginal weighted cones, or biofeedback (based on patient preference, access, and availability), although systematic reviews have not identified any of these modalities as superior over others [<a href="#rid41">41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supervised pelvic floor therapy</strong> – Women who have difficulty performing the exercises or have no improvement with unsupervised exercise may benefit from referral to a pelvic floor physical therapist or continence nurse where available [<a href="#rid42">42</a>]. Pelvic muscle exercises are most effective with specific instruction by health professionals and regular performance by motivated patients. It is not clear how much health care supervision is optimal [<a href="#rid41">41,43</a>]. Both group and individual sessions appear to be helpful [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal weighted cones</strong> – Pelvic muscle exercises can be supplemented by the use of weighted vaginal cones. Vaginal weighted cones are available without a prescription and typically ordered from an online retailer or medical supply store. These may be preferable for women who have insufficient time or resources to dedicate to supervised physical therapy or biofeedback. The patient inserts the cone in the vagina and uses pelvic muscle contractions to hold it in place during activity. A 2013 systematic review and meta-analysis of 23 small randomized trials found some evidence that cones have increased efficacy over no active treatment but inconclusive evidence that they provide increased efficacy over standard pelvic floor muscle exercises [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biofeedback</strong> – Biofeedback as a supplement to pelvic muscle exercises is particularly useful in women who are unable to properly isolate the pelvic floor or use accessory muscles during pelvic floor contractions. This modality involves placement of a vaginal pressure sensor within the vagina that measures pressure and provides an audible or visual feedback of strength of pelvic floor contraction. Augmented versions also use abdominal and perineal electromyography (EMG) recordings to demonstrate improper contraction of abdominal and gluteal muscles. In the United States, biofeedback is covered by Medicare for patients who fail an initial four-week trial of behavioral therapy. Biofeedback is often used in conjunction with supervised pelvic floor physical therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biofeedback alone </strong>– A 2011 systematic review and meta-analysis of 17 randomized or quasi-randomized trials found that, compared with women who received pelvic floor muscle exercises alone, those that also received biofeedback were more likely to report improvement or cure of urinary incontinence (RR 0.75, 95% CI 0.66-0.86) [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With electrical stimulation</strong> – Biofeedback can also be done using electrical stimulation. The device is placed in the vagina or anus and provides a small electrical current that stimulates the pelvic floor muscles to contract, aiding the patient in identification and isolation of the proper muscles. A 2012 review of nine studies found that, compared with sham stimulation, intravaginal electrical stimulation improved continence rates for women with urgency, stress, or mixed incontinence [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With electromyographic biofeedback</strong> – A trial of 600 females comparing pelvic floor muscle therapy with and without electromyographic biofeedback reported similar outcomes in International Consultation on Incontinence Questionnaire-urinary incontinence short form (ICIQ-UI SF, range 0 to 21, higher scores indicate greater severity) scores at 24 months [<a href="#rid48">48</a>]. The addition of electromyographic feedback does not appear to improve long-term outcomes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>With a digital therapeutic device</strong> – An eight-week randomized trial comparing home use of a digital device measuring vaginal motion during pelvic floor contraction (commercial name leva) with a standard home pelvic floor therapy program for patients with SUI reported statistically significant mean reductions in UDI-6 (Urogenital Distress Inventory, Short Form) scores from baseline with device use compared with usual care (mean change 18.8 versus 14.7, respectively) [<a href="#rid49">49,50</a>]. The clinical significance of the magnitude of change is small. There was also a statistically significant reduction in urinary incontinence episodes on three-day diary from a baseline of five to one leaks for the device compared with five to two leaks for the home pelvic floor program (44 versus 29 percent). On planned reassessments at 6 and 12 months, patients using the digital device had twice the odds of reporting improvement compared with control patients (odds ratio 2.45, 95% CI 1.49-4.00) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mobile applications (apps)</strong> – Both free and fee-based apps exist to aid pelvic floor muscle training and address urinary incontinence in females. Their efficacy has been supported by a systematic review of four randomized studies [<a href="#rid52">52</a>]. One study identified 139 mobile apps targeting female stress urinary incontinence; 20 met criteria for review [<a href="#rid53">53</a>]. Of the 20 apps, only one had been trialed and verified in the literature with reported efficacy [<a href="#rid54">54</a>]. Based on the Mobile App Rating Scale (MARS) tool (0 to 5 rating scale), the median MARS for the 20 apps was 3.6, with a range of 2.7 to 4.1 [<a href="#rid53">53</a>].</p><p></p><p>In clinical practice, we use the "just do it" approach. Whatever mode or regimen that will motivate women to perform proper pelvic floor muscle exercise is encouraged. Some may need the motivation of a timed or scheduled appointment with a specialist, while others simply need the encouragement and support to perform the exercise on their own. Recommendations and referrals should be tailored to the patient's preference and needs.</p><p class="headingAnchor" id="H16614795"><span class="h2">Bladder training</span><span class="headingEndMark"> — </span>Bladder training is most effective for women with urgency incontinence [<a href="#rid47">47</a>]. Some women who have stress incontinence only at higher bladder volumes may also benefit from the timed voiding component to keep bladder volumes below that where stress incontinence occurs. Bladder training and pelvic muscle exercises are often used in combination with dietary and lifestyle modifications (eg, fluid restriction to 64 oz/day and avoidance of caffeinated beverages). While evidence supporting bladder training is generally weak, clinical experience supports the practice [<a href="#rid55">55-57</a>].</p><p>Bladder training starts with timed voiding. Patients should keep a voiding diary  (<a class="graphic graphic_form graphicRef69130" href="/z/d/graphic/69130.html" rel="external">form 1</a>) to identify their shortest voiding interval. The shortest voiding interval is used when initiating bladder training. The patient is instructed to void by the clock at regular intervals while awake, using the shortest interval between voids identified on the voiding diary as the initial voiding interval. Urgency between voiding times is controlled with either distraction or mental relaxation techniques (eg, performing mental math, deep breathing) along with quick contractions of the pelvic floor muscles "quick flicks" to suppress urgency and bladder contraction [<a href="#rid14">14</a>]. When the patient can avoid leakage for one day using the initial urination interval, the time between scheduled voids is increased by 15 minutes. The intervals are gradually increased until the patient is voiding every three to four hours without urinary incontinence or frequent urgency.</p><p>A patient bladder training instruction sheet is shown  (<a class="graphic graphic_table graphicRef71150" href="/z/d/graphic/71150.html" rel="external">table 3</a>).</p><p>Successful bladder training can take up to six weeks. Patients often need encouragement and reassurance to continue despite initial lack of response.</p><p>Patients should be encouraged to void regularly even when outside of the home.</p><p class="headingAnchor" id="H16614846"><span class="h2">Topical vaginal estrogen</span><span class="headingEndMark"> — </span>We suggest a trial of vaginal estrogen therapy for peri- or postmenopausal women with either stress or urgency incontinence and vaginal atrophy due to genitourinary syndrome of menopause (GSM). GSM is associated with urinary frequency and dysuria and can contribute to incontinence while treatment with topical estrogen has been associated with symptom improvement [<a href="#rid58">58</a>]. Available preparations include creams, rings, gel caps, and tablets  (<a class="graphic graphic_table graphicRef58506" href="/z/d/graphic/58506.html" rel="external">table 4</a>). We use topical estrogen cream 0.5 gm twice weekly (conjugated estrogen or <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a>), estradiol tablet 10 mcg twice weekly, or the estradiol ring every three months. It may take up to three months for patients to perceive treatment benefit and some patients may require higher doses. The product choice is determined by patient preference, insurance coverage, and ease of use. (See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment"</a>.)</p><p>We do not recommend systemic (oral) estrogen therapy for urinary incontinence. Evidence suggests that systemic hormone therapy may worsen urinary incontinence [<a href="#rid47">47,59,60</a>].</p><p>Systemic absorption is low with topical vaginal estrogen at the recommended initial dose, and major systemic risks appear low [<a href="#rid61">61</a>]. A study of women followed for a mean of seven years found no increases in cardiovascular or cancer-related risks in women using vaginal estrogens compared with non-users [<a href="#rid61">61</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7446.html" rel="external">"Preparations for menopausal hormone therapy", section on 'Low dose'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Serum absorption'</a>.)</p><p></p><p>A systematic review and meta-analysis of four randomized trials of postmenopausal women found that vaginal estrogen was associated with improved continence (RR 0.74; 95% CI 0.64-0.86) [<a href="#rid59">59</a>]. Three of the four trials were restricted to patients with stress incontinence, and statistical heterogeneity between trials limits confidence in the conclusion of the meta-analysis. A subsequent review suggests that vaginal estrogen may be useful as an adjunctive treatment for women with incontinence, although the quality of the evidence was poor to moderate [<a href="#rid62">62</a>].</p><p>The safety of vaginal estrogen in women with a history of breast cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Patients with breast cancer'</a>.)</p><p class="headingAnchor" id="H16614991"><span class="h1">STRESS URINARY INCONTINENCE (SUI) TREATMENT</span><span class="headingEndMark"> — </span>If initial treatments described above are not sufficient for patients with stress incontinence, external support devices may be an effective next step. Patients without adequate relief should be referred for additional treatment options.</p><p class="headingAnchor" id="H3396611220"><span class="h2">Devices</span><span class="headingEndMark"> — </span>Continence pessaries are the most common, traditional form of support devices and may be used for women with stress incontinence either as an adjunct or substitute for pelvic muscle exercises. Overall patient satisfaction rates are approximately 50 percent at one year [<a href="#rid63">63</a>]. These are generally fitted by a gynecologist or urologic continence specialist. An over-the-counter device called the Impressa is also available. (See  <a class="medical medical_review" href="/z/d/html/8081.html" rel="external">"Vaginal pessaries: Indications, devices, and approach to selection"</a>.)</p><p>In unselected patients, the addition of devices to pelvic floor muscle exercises does not appear to improve outcomes over exercises alone [<a href="#rid63">63,64</a>]. However, we find devices can be useful for patients who have stress incontinence that occurs with specific activities or situations (eg, exercising or experiencing an upper respiratory infection with cough-related incontinence).</p><p>Other devices have been developed to be placed within the urethra or vagina to prevent urinary leakage. Their use is limited by high rates of urinary tract infections and lack of evidence regarding long-term safety and efficacy [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H1890993655"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>No pharmacologic therapies have been approved by the US Food and Drug Administration (FDA) for treatment of stress incontinence in women, although multiple medications have been evaluated [<a href="#rid66">66</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">Duloxetine</a> – Duloxetine is a serotonin-norepinephrine reuptake inhibitor that may be effective for incontinence. However, because of potential adverse effects, we do not routinely use duloxetine as treatment for stress incontinence. If patients require treatment for depression, it is reasonable to discuss the option of duloxetine as primary treatment for depression due to the potential benefit of decreasing incontinence.</p><p></p><p class="bulletIndent1">Systematic reviews of <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> in stress urinary incontinence find that treatment is associated with improvements in quality of life, &gt;50 percent reductions in incontinence episodes (relative risk [RR] 1.56; 95% CI 1.46-1.66), and global improvement (RR 1.24; 95% CI 1.14-1.36) but were unable to determine if outcomes were sustainable and noted that one in three patients reported adverse events [<a href="#rid67">67,68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medications</strong> – Alpha-adrenergic agonists (eg, phenylpropanolamine), which stimulate urethral smooth muscle contraction, had been used previously for the treatment of stress incontinence. They are no longer recommended because they are only mildly efficacious compared with placebo and have a high rate of adverse effects [<a href="#rid66">66,69</a>].</p><p></p><p class="bulletIndent1">There is insufficient evidence for the efficacy of <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a> in stress and mixed incontinence, and side effects are significant [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H3320755371"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Women without sufficient improvement with initial treatment and/or pessaries should be evaluated for surgical therapy. For women who desire more rapid and definitive treatment and who are willing to accept surgical risks, surgery offers higher success rates than conservative therapy [<a href="#rid70">70</a>]. Among surgical treatments, midurethral sling procedures have become the standard surgery for SUI because of high cure rates, minimally invasive approach, rapid recovery, and low risk of complications. It is the single most investigated procedure with the strongest evidence justifying its use [<a href="#rid71">71</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8070.html" rel="external">"Female stress urinary incontinence: Choosing a primary surgical procedure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15908.html" rel="external">"Surgical management of stress urinary incontinence in females: Choosing a type of midurethral sling"</a>.)</p><p></p><p>Patients whose symptoms persist despite surgical intervention undergo further evaluation. (See  <a class="medical medical_review" href="/z/d/html/8078.html" rel="external">"Stress urinary incontinence in females: Persistent/recurrent symptoms after surgical treatment"</a>.)</p><p class="headingAnchor" id="H1894544871"><span class="h2">Urethral bulking injections procedures</span><span class="headingEndMark"> — </span>Although urethral bulking injections, also known as periurethral or transurethral injection therapy, result in lower cure rates than other surgeries and often require additional "top-off" injections to achieve maximum efficacy, these procedures have been increasingly used for the primary treatment of SUI because of their less-invasive nature and rapid recovery. Historically, these procedures were reserved for patients with intrinsic sphincteric dysfunction in the setting of a fixed immobile urethra, for those with persistent/recurrent stress urinary incontinence after a standard anti-incontinence surgery, or for individuals unwilling or unable to tolerate a more invasive surgical procedure. (See  <a class="medical medical_review" href="/z/d/html/8078.html" rel="external">"Stress urinary incontinence in females: Persistent/recurrent symptoms after surgical treatment", section on 'Periurethral injection therapy'</a>.)</p><p>The injection of bulking material into the urethral submucosa creates urethral coaptation and resistance, leading to reduced stress incontinence symptoms [<a href="#rid72">72</a>]. Many bulking materials are available with generally poor-quality evidence and challenges with delivery techniques [<a href="#rid73">73,74</a>]. In January 2020, a polyacrylamide gel material was approved by the FDA for use in the United States after a randomized trial versus midurethral sling demonstrated a 64 versus 95 percent satisfaction rate, with 16 percent fewer complications in the bulking injection group [<a href="#rid75">75</a>]. In a systematic review involving 767 patients, the number of incontinence episodes was significantly reduced, and the patients' quality of life was significantly improved, with reinjection rates being reported in 24 percent (range 12 to 35 percent) [<a href="#rid76">76</a>]. Seven-year outcomes on 388 patients show cure or improvement in 67 percent when used as a primary procedure [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H1714698853"><span class="h2">Other specialty treatments</span><span class="headingEndMark"> — </span>Limited data are available for the alternative urinary incontinence treatments listed below. These may be options for patients who do not experience adequate improvement with or decline the established approaches outlined above.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible benefit but limited data</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravesical balloon</strong> – An intravesical balloon device for the treatment of stress urinary incontinence has shown efficacy and safety and has been associated with improved quality of life and satisfaction compared with a sham procedure [<a href="#rid78">78,79</a>]. Long-term follow-up data are needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electrical stimulation of pelvic floor</strong> – In a systematic review, electrical stimulation to improve pelvic floor function using nonimplanted devices was found to be probably more effective than no treatment and maybe not much different than pelvic floor muscle training. There was not enough evidence to determine its relative effectiveness compared with drug therapy or surgery [<a href="#rid80">80</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electroacupuncture</strong> – Electroacupuncture was evaluated in a multicenter randomized trial of 504 women in China with stress urinary incontinence. Compared with sham treatments, a course of 18 active treatments to the lumbosacral region over six weeks reduced urinary leakage by a mean of 10 grams from a baseline of 18 grams. During treatment, the number of incontinence episodes improved from a baseline of eight episodes to one episode per 72-hour interval, with improvement maintained at two episodes per 72 hours approximately six months after the completion of treatment [<a href="#rid81">81</a>]. The availability of this therapy may limit this option; these results require confirmation before its general use can be widely recommended.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulsed magnetic stimulation</strong> – Few quality, randomized controlled trials of pulsed magnetic stimulation suggest marginal improvements in SUI; however, the clinical impact, particularly for episodes of incontinence, and the duration of benefit are not clear [<a href="#rid82">82-84</a>]. A meta-analysis of six trials comparing it with sham treatment showed statistically significant improvements in quality of life and international consultation incontinence questionnaire (ICIQ) scores, but these did not meet the minimum clinically important differences [<a href="#rid85">85</a>]. Reductions in incontinence episodes of 1.42 (95% CI; -2.24 to -0.59) and volume of urine loss of 4.67 gm (95% CI; -8.05 to -1.28) were reported. As there are no trials comparing this therapy to pelvic floor muscle exercises alone, the cost-effectiveness and role of this modality in routine clinical practice is unknown. Availability and insurance coverage may limit this option. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unclear benefit</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaginal laser therapy</strong> – Although initial observational data reported potential improvement of SUI after vaginal laser therapy, clinical trial data are limited. Thus far, there is insufficient evidence to support its use for the routine treatment of SUI. Vaginal laser therapy is an area of active investigation because the treatment is minimally invasive, potentially of lower risk compared with SUI surgery, and generally performed in the office with topical anesthesia. However, vaginal laser therapy also often requires multiple treatment sessions, has unknown duration of effect, and can be costly. It is not approved for clinical use in all countries and generally not covered by insurance. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Sham-controlled trial data</strong> – In a prospective trial of 101 individuals ages 18 to 80 years with SUI, subjective and objective SUI rates were similar between the sham and active groups three months after therapy (subjective SUI: 96 versus 98 percent, relative risk 0.98, 95% CI 0.91-1.05 and objective SUI: 80 percent for both groups, relative risk 0.99, 95% CI 0.81-1.23) [<a href="#rid86">86</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Observational data</strong> – Most of the available evidence is from small, industry-sponsored trials and reported outcomes have been heterogeneous. A meta-analysis of 16 studies including 899 patients suggested there may be a therapeutic benefit with low rate of complications [<a href="#rid87">87</a>], but conclusions were severely limited by lack of randomization and proper control groups as well as potential industry-sponsored biases. </p><p></p><p class="bulletIndent2">The American College of Obstetrics and Gynecology (ACOG) position states there is insufficient evidence to support the use of vaginal laser (CO<sub>2</sub> or erbium) for the treatment of urinary incontinence in the setting of genitourinary syndrome of menopause [<a href="#rid88">88</a>]. Supporting data from larger sham-controlled trials with long-term outcomes assessments are needed before this should be considered appropriate therapy for women with stress incontinence. (See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Laser or radiofrequency devices'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transurethral radiofrequency collagen denaturation</strong> – Transurethral radiofrequency collagen denaturation has been proposed as a minimally invasive device-based intervention to treat urinary incontinence. A systematic review and meta-analysis were able to find only one trial of 173 women that assessed this technology and concluded that it was not known if radiofrequency denaturation improved urinary incontinence symptoms because that outcome was not assessed [<a href="#rid89">89</a>]. In addition, the meta-analysis concluded that there was insufficient evidence to determine if the procedure improved disease-specific quality of life.</p><p></p><p class="headingAnchor" id="H16615237"><span class="h1">URGENCY INCONTINENCE/OVERACTIVE BLADDER (OAB)</span><span class="headingEndMark"> — </span>We generally begin treatment of urgency, urgency-predominant mixed urinary incontinence (MUI), or overactive bladder (OAB) with the same conservative measures that are used for other types of incontinence in women, and we offer medications if initial treatment with incontinence is ineffective [<a href="#rid20">20</a>]. Some women, however, prefer to initiate pharmacologic therapy sooner and may do so without extensive evaluation or invasive testing if symptoms are clear and predominantly urgency-related. Treatment of urgency incontinence/OAB is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment"</a>.)</p><p class="headingAnchor" id="H16615998"><span class="h1">MIXED INCONTINENCE TREATMENT</span><span class="headingEndMark"> — </span>For women with mixed urinary incontinence (MUI), which has components of both stress and urgency incontinence, we start with lifestyle modifications, pelvic floor muscle exercises, and bladder training [<a href="#rid90">90</a>]. A systematic review of five randomized trials found that a combination of pelvic floor exercises and bladder training improved symptoms [<a href="#rid47">47</a>]. (See <a class="local">'Initial treatment'</a> above.)</p><p>If initial treatments above are not effective, women are then treated based on their predominant symptoms (stress or urgency). While there are few data evaluating antimuscarinics in patients with MUI, those with urgency-predominant symptoms are treated similarly to those with pure urgency incontinence [<a href="#rid91">91</a>]. (See <a class="local">'Urgency incontinence/overactive bladder (OAB)'</a> above.)</p><p>If the above interventions do not adequately treat the patient's symptoms, we offer surgical treatment, typically with a mid-urethral sling. Initial concerns that mid-urethral sling insertion could worsen the urgency component have not been supported by data [<a href="#rid16">16,92-94</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 416 women with MUI randomly assigned to receive a mid-urethral sling either with or without behavioral/pelvic floor muscle therapy, both groups reported significant improvement in their symptoms, with the combined treatment group having a greater improvement that, while statistically significant, did not meet the prespecified difference for clinical importance [<a href="#rid95">95</a>]. The retropubic sling improved both stress and urgency urinary incontinence symptoms of MUI, with symptom improvement reported by more than 85 percent of patients overall, and symptom worsening reported by fewer than 5 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the one-year planned follow-up of the study group, while nearly 30 percent of patients (112 of 379) had treatment failure using both subjective and objective criteria, only 15 percent (56 of 379) needed additional treatment, with two of these being for stress incontinence [<a href="#rid96">96</a>].</p><p></p><p>A detailed discussion of surgical management for mixed urinary incontinence is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8070.html" rel="external">"Female stress urinary incontinence: Choosing a primary surgical procedure", section on 'Mixed incontinence'</a>.)</p><p class="headingAnchor" id="H16616082"><span class="h1">OVERFLOW INCONTINENCE</span><span class="headingEndMark"> — </span>Overflow incontinence can mimic stress incontinence, urgency incontinence or mixed urinary incontinence (MUI). Women with overflow incontinence also may present with a variety of symptoms including involuntary, intermittent, or continuous urinary leakage with no warning or sensation, dribbling, and incomplete bladder emptying. Treatment of urinary incontinence associated with impaired bladder emptying depends upon the etiology. (See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Overflow urinary incontinence'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bladder outlet obstruction</strong> – Women with bladder outlet obstruction from previous vaginal or urethral surgery should be referred to a specialist for further evaluation. Obstruction from a large cystocele or uterine prolapse can be treated with a pessary or surgically. (See  <a class="medical medical_review" href="/z/d/html/8072.html" rel="external">"Pelvic organ prolapse in females: Epidemiology, risk factors, clinical manifestations, and management", section on 'Approach to management'</a> and  <a class="medical medical_review" href="/z/d/html/8081.html" rel="external">"Vaginal pessaries: Indications, devices, and approach to selection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detrusor underactivity</strong> – Specific treatment for patients with detrusor underactivity is limited. Potentially reversible causes of impaired emptying should be addressed, for example by stopping medications that impair detrusor contractility and/or result in increased urethral tone  (<a class="graphic graphic_table graphicRef101070" href="/z/d/graphic/101070.html" rel="external">table 2</a>) or by treating constipation. Clean intermittent catheterization may be used to manage overflow incontinence due to detrusor underactivity. (See  <a class="medical medical_review" href="/z/d/html/8090.html" rel="external">"Placement and management of urinary bladder catheters in adults", section on 'Clean intermittent catheterization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic urinary retention</strong> – When there is chronic partial urinary retention (eg, from prior spinal cord injury), clean intermittent catheterization may be used alone or in conjunction with the above approaches (see  <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Bladder dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/8090.html" rel="external">"Placement and management of urinary bladder catheters in adults", section on 'Clean intermittent catheterization'</a>) Chronic transurethral catheterization is not an appropriate long-term management strategy, and these women should be referred for consideration for suprapubic catheterization or urinary diversion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic or neurogenic incontinence</strong> – Sacral nerve stimulation may be beneficial for patients with idiopathic or neurogenic underactivity and Fowler's syndrome. In the United States, it is approved for the treatment of nonobstructive urinary retention. Success rates in general are not as promising as for urgency urinary incontinence and overactive bladder (OAB), and there is a high rate of reintervention within five years due to device malfunction. However, due to the relatively low morbidity and ability to perform a trial phase before permanent implantation, it is generally used prior to more invasive and permanent solutions [<a href="#rid97">97-99</a>].</p><p></p><p class="headingAnchor" id="H16616239"><span class="h1">UNIQUE POPULATIONS</span><span class="headingEndMark"> — </span>When considering treatment for urinary incontinence, special consideration needs to be given to pregnant women or those with cognitive impairment or neurologic disease.</p><p class="headingAnchor" id="H16616245"><span class="h2">Pregnant women</span><span class="headingEndMark"> — </span>The management of pregnant women with urinary incontinence is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8079.html" rel="external">"Effect of pregnancy and childbirth on urinary incontinence and pelvic organ prolapse", section on 'Symptom management during pregnancy'</a>.)</p><p class="headingAnchor" id="H16616263"><span class="h2">Cognitive impairment and functional incontinence</span><span class="headingEndMark"> — </span>When managing incontinence in adults with cognitive impairment, it should not be assumed that the cognitive impairment is the only cause of incontinence. Other factors (eg, functional impairment, comorbid conditions, and medications) should also be investigated and treated. Goals of care and treatment preference discussions should include the needs and wishes of the caregivers who will oversee or implement treatment [<a href="#rid100">100</a>].</p><p>Nonpharmacologic approaches (eg, prompted voiding, scheduling toileting) are preferred in persons with dementia because these individuals are particularly vulnerable to adverse effects of antimuscarinic agents.</p><p>Pharmacotherapies, particularly anticholinergic medications, should be used with caution as women with cognitive impairment may experience more side effects, and beta adrenergic medications as first-line medication should be considered [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/3011.html" rel="external">"Medical care in skilled nursing facilities (SNFs) in the United States", section on 'Urinary incontinence'</a> and  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment", section on 'Adverse drug effects'</a>.)</p><p class="headingAnchor" id="H16616321"><span class="h2">Neurologic disease</span><span class="headingEndMark"> — </span>Adults with specific neurologic diseases (eg, multiple sclerosis, spinal cord injury, Parkinson disease) often have associated bladder or sphincter impairment resulting in complicated mixed stress, urgency and overflow incontinence.</p><p>The treatment of urinary incontinence in adults with neurologic disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Urinary complications'</a>.)</p><p class="headingAnchor" id="H3836242148"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109273.html" rel="external">"Society guideline links: Urinary incontinence in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122885.html" rel="external">"Society guideline links: Gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H16616349"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15357.html" rel="external">"Patient education: Urinary incontinence in females (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15929.html" rel="external">"Patient education: Pelvic floor muscle exercises (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/17199.html" rel="external">"Patient education: Neurogenic bladder in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86013.html" rel="external">"Patient education: Surgery to treat stress urinary incontinence in females (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86014.html" rel="external">"Patient education: Treatments for urgency incontinence in females (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2727.html" rel="external">"Patient education: Urinary incontinence in women (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2726.html" rel="external">"Patient education: Urinary incontinence treatments for women (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/8403.html" rel="external">"Patient education: Pelvic floor muscle exercises (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16616483"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for specialty referral</strong> – Patients with concerning symptoms on presentation (eg, sudden onset of incontinence or associated abdominal/pelvic pain or hematuria in the absence of infection) should be evaluated and/or referred for evaluation of underlying systemic conditions. (See <a class="local">'Identify indications for referral'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior to initiating treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Identify likely type of incontinence </strong>– Determining the classification of urinary incontinence type (stress, urgency, mixed) can help direct treatment. Having a baseline assessment of symptoms (eg, voiding diary, quality of life measures) can facilitate assessment of treatment efficacy. (See  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation", section on 'History'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Address underlying contributory factors</strong> – Before starting any treatment for urinary incontinence, contributory factors such as medical conditions and medications  (<a class="graphic graphic_table graphicRef101070" href="/z/d/graphic/101070.html" rel="external">table 2</a>) should be addressed. (See <a class="local">'Modifying contributory factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment </strong>– We encourage patients to complete initial therapy for six weeks before considering subsequent treatments.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SUI and/or OAB</strong> – We suggest that females with urinary incontinence (stress urinary incontinence [SUI] and/or overactive bladder [OAB]) be instructed to properly perform pelvic muscle (Kegel) exercises (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). These exercises are effective for both stress and urgency urinary incontinence, are minimally invasive, and are effective compared with no intervention. Options to augment exercise compliance such as mobile apps, vaginal weighted cones, and supervised physical therapy should be discussed with patients. (See <a class="local">'Pelvic floor muscle (Kegel) exercises'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoestrogenism</strong> – In peri- or postmenopausal women with vaginal atrophy and either stress or urgency incontinence, we suggest topical vaginal estrogen  (<a class="graphic graphic_table graphicRef58506" href="/z/d/graphic/58506.html" rel="external">table 4</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Topical vaginal estrogen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urgency incontinence</strong> – Patients with urgency incontinence also perform bladder training. (See <a class="local">'Bladder training'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment options</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SUI</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Vaginal incontinence pessary</strong> – For those whose SUI is inadequately treated with lifestyle modification and pelvic floor muscle training, pessaries are offered, particularly to patients who have activity-induced urinary incontinence. Individuals who do not experience adequate relief with a trial of incontinence pessary should be referred for other options. (See <a class="local">'Devices'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Surgery</strong> – For patients who desire rapid and definitive treatment or who have had inadequate symptom improvement with initial therapy, the midurethral sling (a minimally invasive surgical option) offers higher success rates than conservative therapy. Patients must be willing to accept the inherent risks of surgery. (See <a class="local">'Surgery'</a> above and  <a class="medical medical_review" href="/z/d/html/8070.html" rel="external">"Female stress urinary incontinence: Choosing a primary surgical procedure"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Urethral bulking injections</strong> – Less invasive options, such as urethral bulking, may be offered even as a primary stress incontinence procedure with the understanding that efficacy may be lower than that of traditional surgeries. (See <a class="local">'Urethral bulking injections procedures'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Treatments with uncertain benefit</strong> – While other treatment options exist, supporting data are inadequate to advise routine use of these modalities for those with SUI. Patients should be counseled that there is currently insufficient quality evidence to support use of vaginal laser treatments for stress urinary incontinence and these treatments can be costly and not covered by insurance. (See <a class="local">'Other specialty treatments'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>OAB </strong>– Initial treatment of OAB is the same as for SUI and includes pelvic floor muscle training and lifestyle modifications. Additional treatment options include medication, injections of botulinum toxin, and/or sacral neuromodulation. (See <a class="local">'Urgency incontinence/overactive bladder (OAB)'</a> above and  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed urinary incontinence</strong> – Treatment of mixed urinary incontinence (MUI) should begin with lifestyle modification and pelvic floor muscle training. Subsequent therapy should be focused first on alleviation of symptoms causing most degree of bother. While surgical treatment of stress symptoms may improve urgency symptoms, surgery should not be considered as a primary treatment for refractory urge incontinence. (See <a class="local">'Mixed incontinence treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overflow incontinence</strong> – Treatment of overflow incontinence is specific to the etiology. (See <a class="local">'Overflow incontinence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unique populations</strong> – When beginning initial treatment for urinary incontinence, special consideration needs to be given to women who are pregnant or who have cognitive impairment or other neurologic disease. (See <a class="local">'Unique populations'</a> above and  <a class="medical medical_review" href="/z/d/html/8079.html" rel="external">"Effect of pregnancy and childbirth on urinary incontinence and pelvic organ prolapse", section on 'Symptom management during pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H7940752"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Catherine E DuBeau, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.</a></li><li><a class="nounderline abstract_t">Minassian VA, Yan X, Lichtenfeld MJ, et al. The iceberg of health care utilization in women with urinary incontinence. Int Urogynecol J 2012; 23:1087.</a></li><li><a class="nounderline abstract_t">Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary Incontinence in Women: A Review. JAMA 2017; 318:1592.</a></li><li><a class="nounderline abstract_t">Jarbøl DE, Haastrup PF, Rasmussen S, et al. Women's barriers for contacting their general practitioner when bothered by urinary incontinence: a population-based cross-sectional study. BMC Urol 2021; 21:99.</a></li><li><a class="nounderline abstract_t">Harris SS, Link CL, Tennstedt SL, et al. Care seeking and treatment for urinary incontinence in a diverse population. J Urol 2007; 177:680.</a></li><li><a class="nounderline abstract_t">Blaivas JG, Panagopoulos G, Weiss JP, Somaroo C. Validation of the overactive bladder symptom score. J Urol 2007; 178:543.</a></li><li><a class="nounderline abstract_t">Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn 2015; 34:255.</a></li><li><a class="nounderline abstract_t">Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003; 189:98.</a></li><li><a class="nounderline abstract_t">Beeson T, Davis C. Urinary Management With an External Female Collection Device. J Wound Ostomy Continence Nurs 2018; 45:187.</a></li><li><a class="nounderline abstract_t">Uhr A, Glick L, Barron S, et al. How I Do It: PureWick female external catheter: a non-invasive urine management system for incontinent women. Can J Urol 2021; 28:10669.</a></li><li><a class="nounderline abstract_t">Zavodnick J, Harley C, Zabriskie K, Brahmbhatt Y. Effect of a Female External Urinary Catheter on Incidence of Catheter-Associated Urinary Tract Infection. Cureus 2020; 12:e11113.</a></li><li><a class="nounderline abstract_t">Root N, Horigan AE, Lough ME. External Female Urinary Catheter: Implementation in the Emergency Department. J Emerg Nurs 2021; 47:131.</a></li><li><a class="nounderline abstract_t">Eckert L, Mattia L, Patel S, et al. Reducing the Risk of Indwelling Catheter-Associated Urinary Tract Infection in Female Patients by Implementing an Alternative Female External Urinary Collection Device: A Quality Improvement Project. J Wound Ostomy Continence Nurs 2020; 47:50.</a></li><li><a class="nounderline abstract_t">Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med 2010; 363:1156.</a></li><li><a class="nounderline abstract_t">Rogers RG. Clinical practice. Urinary stress incontinence in women. N Engl J Med 2008; 358:1029.</a></li><li><a class="nounderline abstract_t">Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29:213.</a></li><li><a class="nounderline abstract_t">Hajiha M, Elterman D. Urinary urgency and frequency in a 53-year-old woman. CMAJ 2016; 188:59.</a></li><li><a class="nounderline abstract_t">Olivera CK, Meriwether K, El-Nashar S, et al. Nonantimuscarinic treatment for overactive bladder: a systematic review. Am J Obstet Gynecol 2016; 215:34.</a></li><li><a class="nounderline abstract_t">Vo A, Kielb SJ. Female Voiding Dysfunction and Urinary Incontinence. Med Clin North Am 2018; 102:313.</a></li><li><a class="nounderline abstract_t">Balk EM, Rofeberg VN, Adam GP, et al. Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A Systematic Review and Network Meta-analysis of Clinical Outcomes. Ann Intern Med 2019; 170:465.</a></li><li class="breakAll">DuBeau CE, Kuchel GA, Johnson T, et al.. Incontinence in the frail elderly. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications Ltd, Paris 2009. p.961.</li><li><a class="nounderline abstract_t">Imamura M, Williams K, Wells M, McGrother C. Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev 2015; :CD003505.</a></li><li><a class="nounderline abstract_t">Brown HW, Braun EJ, Wise ME, et al. Small-Group, Community-Member Intervention for Urinary and Bowel Incontinence: A Randomized Controlled Trial. Obstet Gynecol 2019; 134:600.</a></li><li><a class="nounderline abstract_t">Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009; 360:481.</a></li><li><a class="nounderline abstract_t">Brown JS, Wing R, Barrett-Connor E, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care 2006; 29:385.</a></li><li><a class="nounderline abstract_t">Wing RR, West DS, Grady D, et al. Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. J Urol 2010; 184:1005.</a></li><li><a class="nounderline abstract_t">Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol 2012; 187:939.</a></li><li><a class="nounderline abstract_t">Yazdany T, Jakus-Waldman S, Jeppson PC, et al. American Urogynecologic Society Systematic Review: The Impact of Weight Loss Intervention on Lower Urinary Tract Symptoms and Urinary Incontinence in Overweight and Obese Women. Female Pelvic Med Reconstr Surg 2020; 26:16.</a></li><li><a class="nounderline abstract_t">Hagovska M, Švihra J, Buková A, et al. Effect of an exercise programme for reducing abdominal fat on overactive bladder symptoms in young overweight women. Int Urogynecol J 2020; 31:895.</a></li><li><a class="nounderline abstract_t">Sheridan W, Da Silva AS, Leca BM, et al. Weight loss with bariatric surgery or behaviour modification and the impact on female obesity-related urine incontinence: A comprehensive systematic review and meta-analysis. Clin Obes 2021; 11:e12450.</a></li><li><a class="nounderline abstract_t">Bradley CS, Erickson BA, Messersmith EE, et al. Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review. J Urol 2017; 198:1010.</a></li><li><a class="nounderline abstract_t">Gleason JL, Richter HE, Redden DT, et al. Caffeine and urinary incontinence in US women. Int Urogynecol J 2013; 24:295.</a></li><li><a class="nounderline abstract_t">Dallosso HM, McGrother CW, Matthews RJ, et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 2003; 92:69.</a></li><li><a class="nounderline abstract_t">Wood LN, Anger JT. Urinary incontinence in women. BMJ 2014; 349:g4531.</a></li><li><a class="nounderline abstract_t">Tähtinen RM, Auvinen A, Cartwright R, et al. Smoking and bladder symptoms in women. Obstet Gynecol 2011; 118:643.</a></li><li><a class="nounderline abstract_t">Culbertson S, Davis AM. Nonsurgical Management of Urinary Incontinence in Women. JAMA 2017; 317:79.</a></li><li class="breakAll">Pelvic floor muscle training: a practical guide. British Medical Journal. BMJ 2022;327:3070186. Sept 2022. https://www.bmj.com/content/378/bmj-2022-070186 (Accessed on September 15, 2022).</li><li><a class="nounderline abstract_t">Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2018; 10:CD005654.</a></li><li class="breakAll">Hay-Smith J, Berghmans BK, et al.. Adult conservative management. In: Incontinence, 4th Ed., Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications Ltd, Paris 2009. p.1025.</li><li><a class="nounderline abstract_t">Brink CA, Wells TJ, Sampselle CM, et al. A digital test for pelvic muscle strength in women with urinary incontinence. Nurs Res 1994; 43:352.</a></li><li><a class="nounderline abstract_t">Hay-Smith EJ, Herderschee R, Dumoulin C, Herbison GP. Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2011; :CD009508.</a></li><li><a class="nounderline abstract_t">Fitz FF, Gimenez MM, de Azevedo Ferreira L, et al. Pelvic floor muscle training for female stress urinary incontinence: a randomised control trial comparing home and outpatient training. Int Urogynecol J 2020; 31:989.</a></li><li><a class="nounderline abstract_t">Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2010; :CD005654.</a></li><li><a class="nounderline abstract_t">Dumoulin C, Morin M, Danieli C, et al. Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial. JAMA Intern Med 2020; 180:1284.</a></li><li><a class="nounderline abstract_t">Herbison GP, Dean N. Weighted vaginal cones for urinary incontinence. Cochrane Database Syst Rev 2013; :CD002114.</a></li><li><a class="nounderline abstract_t">Herderschee R, Hay-Smith EJ, Herbison GP, et al. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2011; :CD009252.</a></li><li class="breakAll">Effective Health Care Program. Nonsurgical treatments for urinary incontinence in adult women: Diagnosis and comparative effectiveness. Agency for Healthcare Research Quality 2012. Available at: https://effectivehealthcare.ahrq.gov/products/urinary-incontinence-treatment/research (Accessed on November 19, 2012).</li><li><a class="nounderline abstract_t">Hagen S, Elders A, Stratton S, et al. Effectiveness of pelvic floor muscle training with and without electromygraphic biofeedback for urinary incontinence in women: Multicentre randomised controlled trial. BMJ 2020; 371:m3719.</a></li><li><a class="nounderline abstract_t">Weinstein MM, Dunivan G, Guaderrama NM, Richter HE. Digital Therapeutic Device for Urinary Incontinence: A Randomized Controlled Trial. Obstet Gynecol 2022; 139:606.</a></li><li><a class="nounderline abstract_t">Weinstein MM, Pulliam SJ, Richter HE. Randomized trial comparing efficacy of pelvic floor muscle training with a digital therapeutic motion-based device to standard pelvic floor exercises for treatment of stress urinary incontinence (SUV trial): An all-virtual trial design. Contemp Clin Trials 2021; 105:106406.</a></li><li><a class="nounderline abstract_t">Weinstein MM, Dunivan GC, Guaderrama NM, Richter HE. Digital Therapeutic Device for Urinary Incontinence; A Longitudinal Analysis at 6 and 12 Months. Obstet Gynecol 2023; 141:199.</a></li><li><a class="nounderline abstract_t">Widdison R, Rashidi A, Whitehead L. Effectiveness of mobile apps to improve urinary incontinence: a systematic review of randomised controlled trials. BMC Nurs 2022; 21:32.</a></li><li><a class="nounderline abstract_t">Ho L, Macnab A, Matsubara Y, et al. Rating of Pelvic Floor Muscle Training Mobile Applications for Treatment of Urinary Incontinence in Women. Urology 2021; 150:92.</a></li><li><a class="nounderline abstract_t">Asklund I, Nyström E, Sjöström M, et al. Mobile app for treatment of stress urinary incontinence: A randomized controlled trial. Neurourol Urodyn 2017; 36:1369.</a></li><li><a class="nounderline abstract_t">Ostaszkiewicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2004; 2004:CD002802.</a></li><li><a class="nounderline abstract_t">Ostaszkiewicz J, Johnston L, Roe B. Habit retraining for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2004; :CD002801.</a></li><li><a class="nounderline abstract_t">Roe B, Ostaszkiewicz J, Milne J, Wallace S. Systematic reviews of bladder training and voiding programmes in adults: a synopsis of findings from data analysis and outcomes using metastudy techniques. J Adv Nurs 2007; 57:15.</a></li><li><a class="nounderline abstract_t">Christmas MM, Iyer S, Daisy C, et al. Menopause hormone therapy and urinary symptoms: a systematic review. Menopause 2023; 30:672.</a></li><li><a class="nounderline abstract_t">Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10:CD001405.</a></li><li><a class="nounderline abstract_t">Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005; 293:935.</a></li><li><a class="nounderline abstract_t">Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 2018; 25:11.</a></li><li><a class="nounderline abstract_t">Rahn DD, Ward RM, Sanses TV, et al. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 2015; 26:3.</a></li><li><a class="nounderline abstract_t">Richter HE, Burgio KL, Brubaker L, et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial. Obstet Gynecol 2010; 115:609.</a></li><li><a class="nounderline abstract_t">Ayeleke RO, Hay-Smith EJ, Omar MI. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. Cochrane Database Syst Rev 2015; 2015:CD010551.</a></li><li><a class="nounderline abstract_t">Lipp A, Shaw C, Glavind K. Mechanical devices for urinary incontinence in women. Cochrane Database Syst Rev 2014; :CD001756.</a></li><li><a class="nounderline abstract_t">Malallah MA, Al-Shaiji TF. Pharmacological treatment of pure stress urinary incontinence: a narrative review. Int Urogynecol J 2015; 26:477.</a></li><li><a class="nounderline abstract_t">Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 2005; :CD004742.</a></li><li><a class="nounderline abstract_t">Li J, Yang L, Pu C, et al. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int Urol Nephrol 2013; 45:679.</a></li><li><a class="nounderline abstract_t">Zinner NR, Koke SC, Viktrup L. Pharmacotherapy for stress urinary incontinence : present and future options. Drugs 2004; 64:1503.</a></li><li><a class="nounderline abstract_t">Labrie J, Berghmans BL, Fischer K, et al. Surgery versus physiotherapy for stress urinary incontinence. N Engl J Med 2013; 369:1124.</a></li><li><a class="nounderline abstract_t">Imamura M, Hudson J, Wallace SA, et al. Surgical interventions for women with stress urinary incontinence: systematic review and network meta-analysis of randomised controlled trials. BMJ 2019; 365:l1842.</a></li><li><a class="nounderline abstract_t">Hoe V, Haller B, Yao HH, O'Connell HE. Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review. Neurourol Urodyn 2021; 40:1349.</a></li><li><a class="nounderline abstract_t">Davis NF, Kheradmand F, Creagh T. Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. Int Urogynecol J 2013; 24:913.</a></li><li><a class="nounderline abstract_t">Hussain SM, Bray R. Urethral bulking agents for female stress urinary incontinence. Neurourol Urodyn 2019; 38:887.</a></li><li><a class="nounderline abstract_t">Itkonen Freitas AM, Mikkola TS, Rahkola-Soisalo P, et al. Quality of life and sexual function after TVT surgery versus Bulkamid injection for primary stress urinary incontinence: 1 year results from a randomized clinical trial. Int Urogynecol J 2021; 32:595.</a></li><li><a class="nounderline abstract_t">Kasi AD, Pergialiotis V, Perrea DN, et al. Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature. Int Urogynecol J 2016; 27:367.</a></li><li><a class="nounderline abstract_t">Brosche T, Kuhn A, Lobodasch K, Sokol ER. Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. Neurourol Urodyn 2021; 40:502.</a></li><li><a class="nounderline abstract_t">Wyndaele JJ, De Wachter S, Tommaselli GA, et al. A randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of stress urinary incontinence in females. Neurourol Urodyn 2016; 35:252.</a></li><li><a class="nounderline abstract_t">Winkler H, Jacoby K, Kalota S, et al. Twelve-Month Efficacy and Safety Data for the "Stress Incontinence Control, Efficacy and Safety Study": A Phase III, Multicenter, Prospective, Randomized, Controlled Study Treating Female Stress Urinary Incontinence Using the Vesair Intravesical Balloon. Female Pelvic Med Reconstr Surg 2018; 24:222.</a></li><li><a class="nounderline abstract_t">Stewart F, Berghmans B, Bø K, Glazener CM. Electrical stimulation with non-implanted devices for stress urinary incontinence in women. Cochrane Database Syst Rev 2017; 12:CD012390.</a></li><li><a class="nounderline abstract_t">Liu Z, Liu Y, Xu H, et al. Effect of Electroacupuncture on Urinary Leakage Among Women With Stress Urinary Incontinence: A Randomized Clinical Trial. JAMA 2017; 317:2493.</a></li><li><a class="nounderline abstract_t">Lim R, Liong ML, Leong WS, et al. Pulsed Magnetic Stimulation for Stress Urinary Incontinence: 1-Year Followup Results. J Urol 2017; 197:1302.</a></li><li><a class="nounderline abstract_t">Hou WH, Lin PC, Lee PH, et al. Effects of extracorporeal magnetic stimulation on urinary incontinence: A systematic review and meta-analysis. J Adv Nurs 2020; 76:2286.</a></li><li><a class="nounderline abstract_t">Sun K, Zhang D, Wu G, et al. Efficacy of magnetic stimulation for female stress urinary incontinence: a meta-analysis. Ther Adv Urol 2021; 13:17562872211032485.</a></li><li><a class="nounderline abstract_t">Lim R, Liong ML, Lim KK, et al. The Minimum Clinically Important Difference of the International Consultation on Incontinence Questionnaires (ICIQ-UI SF and ICIQ-LUTSqol). Urology 2019; 133:91.</a></li><li><a class="nounderline abstract_t">Alexander JW, Karjalainen P, Ow LL, et al. CO2 surgical laser for treatment of stress urinary incontinence in women: a randomized controlled trial. Am J Obstet Gynecol 2022; 227:473.e1.</a></li><li><a class="nounderline abstract_t">Wang Y, Wang C, Song F, et al. Safety and efficacy of vaginal laser therapy for stress urinary incontinence: a meta-analysis. Ann Palliat Med 2021; 10:2736.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. Female Sexual Dysfunction: ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists, Number 213. Obstet Gynecol 2019; 134:e1.</a></li><li><a class="nounderline abstract_t">Kang D, Han J, Neuberger MM, et al. Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence. Cochrane Database Syst Rev 2015; :CD010217.</a></li><li><a class="nounderline abstract_t">Myers DL. Female mixed urinary incontinence: a clinical review. JAMA 2014; 311:2007.</a></li><li><a class="nounderline abstract_t">Gomelsky A, Dmochowski RR. Treatment of mixed urinary incontinence in women. Curr Opin Obstet Gynecol 2011; 23:371.</a></li><li><a class="nounderline abstract_t">Kobashi KC, Albo ME, Dmochowski RR, et al. Surgical Treatment of Female Stress Urinary Incontinence: AUA/SUFU Guideline. J Urol 2017; 198:875.</a></li><li><a class="nounderline abstract_t">Welk B, Baverstock RJ. The management of mixed urinary incontinence in women. Can Urol Assoc J 2017; 11:S121.</a></li><li><a class="nounderline abstract_t">Dmochowski RR, Blaivas JM, Gormley EA, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. J Urol 2010; 183:1906.</a></li><li><a class="nounderline abstract_t">Sung VW, Borello-France D, Newman DK, et al. Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial. JAMA 2019; 322:1066.</a></li><li><a class="nounderline abstract_t">Sung VW, Richter HE, Moalli P, et al. Characteristics Associated With Treatment Failure 1 Year After Midurethral Sling in Women With Mixed Urinary Incontinence. Obstet Gynecol 2021; 138:199.</a></li><li><a class="nounderline abstract_t">Noblett KL, Cadish LA. Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction. Am J Obstet Gynecol 2014; 210:99.</a></li><li><a class="nounderline abstract_t">Gross C, Habli M, Lindsell C, South M. Sacral neuromodulation for nonobstructive urinary retention: a meta-analysis. Female Pelvic Med Reconstr Surg 2010; 16:249.</a></li><li><a class="nounderline abstract_t">Chughtai B, Thomas D, Sun T, Sedrakyan A. Failures of Sacral Neuromodulation for Incontinence. JAMA Surg 2018; 153:493.</a></li><li><a class="nounderline abstract_t">Pfisterer MH, Johnson TM 2nd, Jenetzky E, et al. Geriatric patients' preferences for treatment of urinary incontinence: a study of hospitalized, cognitively competent adults aged 80 and older. J Am Geriatr Soc 2007; 55:2016.</a></li><li><a class="nounderline abstract_t">Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193:1572.</a></li></ol></div><div id="topicVersionRevision">Topic 6881 Version 97.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857671" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22527544" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The iceberg of health care utilization in women with urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29067433" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Urinary Incontinence in Women: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34247613" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Women's barriers for contacting their general practitioner when bothered by urinary incontinence: a population-based cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222656" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Care seeking and treatment for urinary incontinence in a diverse population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17570417" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Validation of the overactive bladder symptom score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25783168" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12861145" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Validation of two global impression questionnaires for incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29394218" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Urinary Management With an External Female Collection Device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34129459" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : How I Do It: PureWick female external catheter: a non-invasive urine management system for incontinent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33240709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of a Female External Urinary Catheter on Incidence of Catheter-Associated Urinary Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33187721" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : External Female Urinary Catheter: Implementation in the Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31929443" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reducing the Risk of Indwelling Catheter-Associated Urinary Tract Infection in Female Patients by Implementing an Alternative Female External Urinary Collection Device: A Quality Improvement Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843250" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical practice. Idiopathic urgency urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322284" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical practice. Urinary stress incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20025020" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598377" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Urinary urgency and frequency in a 53-year-old woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26851599" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nonantimuscarinic treatment for overactive bladder: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29406060" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Female Voiding Dysfunction and Urinary Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30884526" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A Systematic Review and Network Meta-analysis of Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30884526" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A Systematic Review and Network Meta-analysis of Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630349" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lifestyle interventions for the treatment of urinary incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31403596" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Small-Group, Community-Member Intervention for Urinary and Bowel Incontinence: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179316" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Weight loss to treat urinary incontinence in overweight and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443892" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643425" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22264468" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860569" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : American Urogynecologic Society Systematic Review: The Impact of Weight Loss Intervention on Lower Urinary Tract Symptoms and Urinary Incontinence in Overweight and Obese Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31773200" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of an exercise programme for reducing abdominal fat on overactive bladder symptoms in young overweight women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33955687" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Weight loss with bariatric surgery or behaviour modification and the impact on female obesity-related urine incontinence: A comprehensive systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28479236" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22699886" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Caffeine and urinary incontinence in US women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823386" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225003" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860295" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Smoking and bladder symptoms in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28030686" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonsurgical Management of Urinary Incontinence in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28030686" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nonsurgical Management of Urinary Incontinence in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30288727" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30288727" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7971299" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A digital test for pelvic muscle strength in women with urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161451" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444535" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pelvic floor muscle training for female stress urinary incontinence: a randomised control trial comparing home and outpatient training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091581" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32744599" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23836411" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Weighted vaginal cones for urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735442" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735442" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effectiveness of pelvic floor muscle training with and without electromygraphic biofeedback for urinary incontinence in women: Multicentre randomised controlled trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35271539" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Digital Therapeutic Device for Urinary Incontinence: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33866003" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Randomized trial comparing efficacy of pelvic floor muscle training with a digital therapeutic motion-based device to standard pelvic floor exercises for treatment of stress urinary incontinence (SUV trial): An all-virtual trial design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Digital Therapeutic Device for Urinary Incontinence; A Longitudinal Analysis at 6 and 12 Months</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35090464" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effectiveness of mobile apps to improve urinary incontinence: a systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32890617" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rating of Pelvic Floor Muscle Training Mobile Applications for Treatment of Urinary Incontinence in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27611958" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mobile app for treatment of stress urinary incontinence: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14973993" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Timed voiding for the management of urinary incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106179" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Habit retraining for the management of urinary incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17184371" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Systematic reviews of bladder training and voiding programmes in adults: a synopsis of findings from data analysis and outcomes using metastudy techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37192832" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Menopause hormone therapy and urinary symptoms: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076892" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Oestrogen therapy for urinary incontinence in post-menopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728164" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of estrogen with and without progestin on urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28816933" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25392183" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177294" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526663" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517397" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mechanical devices for urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25630399" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pharmacological treatment of pure stress urinary incontinence: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034945" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23504618" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15233589" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pharmacotherapy for stress urinary incontinence : present and future options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24047061" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Surgery versus physiotherapy for stress urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31167796" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Surgical interventions for women with stress urinary incontinence: systematic review and network meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34015151" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23224022" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30801773" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Urethral bulking agents for female stress urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33275162" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Quality of life and sexual function after TVT surgery versus Bulkamid injection for primary stress urinary incontinence: 1 year results from a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209952" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33410544" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25598453" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of stress urinary incontinence in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28953076" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Twelve-Month Efficacy and Safety Data for the "Stress Incontinence Control, Efficacy and Safety Study": A Phase III, Multicenter, Prospective, Randomized, Controlled Study Treating Female Stress Urinary Incontinence Using the Vesair Intravesical Balloon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29271482" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Electrical stimulation with non-implanted devices for stress urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28655016" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of Electroacupuncture on Urinary Leakage Among Women With Stress Urinary Incontinence: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27871927" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pulsed Magnetic Stimulation for Stress Urinary Incontinence: 1-Year Followup Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32538469" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effects of extracorporeal magnetic stimulation on urinary incontinence: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34345251" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy of magnetic stimulation for female stress urinary incontinence: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31415780" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The Minimum Clinically Important Difference of the International Consultation on Incontinence Questionnaires (ICIQ-UI SF and ICIQ-LUTSqol).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35662546" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : CO2 surgical laser for treatment of stress urinary incontinence in women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33549008" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Safety and efficacy of vaginal laser therapy for stress urinary incontinence: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31241598" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Female Sexual Dysfunction: ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists, Number 213.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785555" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846038" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Female mixed urinary incontinence: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836506" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of mixed urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28625508" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Surgical Treatment of Female Stress Urinary Incontinence: AUA/SUFU Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28616109" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The management of mixed urinary incontinence in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20303102" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Update of AUA guideline on the surgical management of female stress urinary incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31529007" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237755" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Characteristics Associated With Treatment Failure 1 Year After Midurethral Sling in Women With Mixed Urinary Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899452" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453352" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Sacral neuromodulation for nonobstructive urinary retention: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29450441" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Failures of Sacral Neuromodulation for Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17979956" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Geriatric patients' preferences for treatment of urinary incontinence: a study of hospitalized, cognitively competent adults aged 80 and older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623739" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
